

Intra-Cellular Therapies, Inc.  
 Form 3  
 September 09, 2013

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Wennogle Lawrence P. (Last) (First) (Middle)  C/O INTRA-CELLULAR THERAPIES, INC., Â 3960 BROADWAY (Street)  NEW YORK, Â NY Â 10032 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/29/2013	3. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [NONE]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Vice President, Drug Discovery	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--	--	--	---

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	100,000	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

## Edgar Filing: Intra-Cellular Therapies, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	Â <u>(1)</u>	12/16/2013	Common Stock	12,500	\$ 0.3	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	12/19/2014	Common Stock	37,500	\$ 0.5	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	12/14/2015	Common Stock	12,500	\$ 0.6	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	12/05/2016	Common Stock	12,500	\$ 1.36	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	12/12/2017	Common Stock	12,500	\$ 1.5	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	12/18/2018	Common Stock	10,000	\$ 1.5	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	06/10/2020	Common Stock	10,000	\$ 2.74	D	Â
Stock Option (right to buy)	Â <u>(2)</u>	12/21/2020	Common Stock	10,000	\$ 2.74	D	Â
Stock Option (right to buy)	Â <u>(3)</u>	04/30/2022	Common Stock	5,000	\$ 2.84	D	Â
Stock Option (right to buy)	Â <u>(4)</u>	05/30/2023	Common Stock	7,500	\$ 3.26	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships				Other
	Director	10% Owner	Officer		
Wennogle Lawrence P. C/O INTRA-CELLULAR THERAPIES, INC. 3960 BROADWAY NEW YORK, NY 10032	Â	Â	Â Vice President, Drug Discovery	Â	

## Signatures

/s/ Lawrence J. Hineline,  
Attorney-in-fact

09/09/2013

     \*\*Signature of Reporting Person

    Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) All shares underlying this option have vested.
- (2)

## Edgar Filing: Intra-Cellular Therapies, Inc. - Form 3

The option vests as to one third of the shares on December 22, 2011, one third of the shares on December 22, 2012 and one third of the shares on December 22, 2013.

- (3) The option vests as to one third of the shares on December 20, 2012, one third of the shares on December 20, 2013 and one third of the shares on December 20, 2014.
- (4) The option vests as to one third of the shares on December 20, 2013, one third of the shares on December 20, 2014 and one third of the shares on December 20, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.